Investor Presentaiton
SARTATE™M - next generation theranostic
SARTATE™ is a highly targeted theranostic radiopharmaceutical which is being developed for diagnosing, staging and
subsequently treating cancers that express somatostatin receptor 2 (SSTR2)
Current clinical development
•
•
64CU SARTATE™M for the management of neuroblastoma
67 CU SARTATETM for the treatment of neuroblastoma
64CU SARTATE™M for the management of NETS
Future opportunities
Other SSTR2 positive diseases, including but not limited to pancreatic
and gastrointestinal cancer, pulmonary NETs, meningiomas
Regulatory milestones
Rare
Paediatric
Disease
Designation
US FDA Rare Paediatric Disease Designation (RPDD) for:
67 CU SARTATE™M granted (neuroblastoma therapy)
64CU SARTATEM granted (management of neuroblastoma)
Orphan Drug
Designation
US FDA Orphan Drug Designation (ODD) for:
67 CU SARTATE™ granted (neuroblastoma therapy)
64 CU SARTATE™M granted (management of neuroblastoma)
RPDDs may potentially allow to access 2 Priority Review Vouchers, which
are tradeable and have recently transacted at approximately US$110M
CLARITY
2014 M
High Accuracy
High Precision
123 MIBG
64CU SARTATE™M
Current Standard of
Care
PET screening
4 hours
(in the same patient)
67 CU SARTATE™M
SPECT scan
24 hours
20View entire presentation